These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23153688)

  • 1. Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk.
    Abad-Cardiel M; Alvarez-Álvarez B; Luque-Fernandez L; Fernández C; Fernández-Cruz A; Martell-Claros N
    Rev Esp Cardiol (Engl Ed); 2013 Jan; 66(1):47-52. PubMed ID: 23153688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence of primary aldosteronism in hypertensive patients and its effect on the heart].
    Morillas P; Castillo J; Quiles J; Núñez D; Guillén S; Bertomeu-González V; Pomares F; Bertomeu V
    Rev Esp Cardiol; 2008 Apr; 61(4):418-21. PubMed ID: 18405523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect.
    Hernández-delRey R; Armario P; Martin-Baranera M; Sánchez P; Cárdenas G; Pardell H
    Blood Press Monit; 1998; 3(6):331-7. PubMed ID: 10212374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension].
    Mosso L; Fardella C; Montero J; Rojas P; Sánchez O; Rojas V; Rojas A; Huete A; Soto J; Foradori A
    Rev Med Chil; 1999 Jul; 127(7):800-6. PubMed ID: 10668287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone excess and resistance to 24-h blood pressure control.
    Pimenta E; Gaddam KK; Pratt-Ubunama MN; Nishizaka MK; Cofield SS; Oparil S; Calhoun DA
    J Hypertens; 2007 Oct; 25(10):2131-7. PubMed ID: 17885558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism.
    Prejbisz A; Postuła M; Cybulska I; Dobrucki T; Kabat M; Peczkowska M; Janas J; Janaszek-Sitkowska H; Makowiecka-Cieśla M; Januszkiewicz A
    Kardiol Pol; 2003 Jan; 58(1):17-26. PubMed ID: 14502298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What tests should be conducted for secondary arterial hypertension in hypertensive patients resistant to treatment?].
    Denolle T; Hanon O; Mounier-Vehier C; Marquand A; Fauvel JP; Laurent P; Tison E; Equine O; Ducloux D; Girerd X
    Arch Mal Coeur Vaiss; 2000 Aug; 93(8):1037-9. PubMed ID: 10989753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary hyperaldosteronism in hypertension].
    Girerd X
    Rev Med Suisse; 2008 Sep; 4(170):1924-6. PubMed ID: 18847121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation in primary aldosteronism.
    Watson T; Karthikeyan VJ; Lip GY; Beevers DG
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):190-4. PubMed ID: 19617274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in patients with primary aldosteronism after treatment.
    Catena C; Colussi G; Nadalini E; Chiuch A; Baroselli S; Lapenna R; Sechi LA
    Arch Intern Med; 2008 Jan; 168(1):80-5. PubMed ID: 18195199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.
    Milliez P; Girerd X; Plouin PF; Blacher J; Safar ME; Mourad JJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1243-8. PubMed ID: 15837256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of aldosterone in left ventricular hypertrophy in hypertension.
    Matsumura K; Fujii K; Oniki H; Oka M; Iida M
    Am J Hypertens; 2006 Jan; 19(1):13-8. PubMed ID: 16461184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between blood pressure and circulating hormonal factors with left ventricular mass in patients with essential hypertension older than 55 years of age].
    González Quijada S; Luque Otero M; Fernández-Cruz A; Almería C; Bagazgoitia Barrera J; Moya Marín FJ
    Med Clin (Barc); 1997 Oct; 109(12):441-4. PubMed ID: 9441177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment.
    Turchi F; Ronconi V; di Tizio V; Ceccoli L; Boscaro M; Giacchetti G
    Nutr Metab Cardiovasc Dis; 2014 May; 24(5):476-82. PubMed ID: 24630976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk].
    Widimský J
    Vnitr Lek; 2013 Jun; 59(6):501-4. PubMed ID: 23808747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension.
    Shigematsu Y; Hamada M; Mukai M; Matsuoka H; Sumimoto T; Hiwada K
    J Hypertens; 1995 Jan; 13(1):155-60. PubMed ID: 7759846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study.
    Savard S; Amar L; Plouin PF; Steichen O
    Hypertension; 2013 Aug; 62(2):331-6. PubMed ID: 23753408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.
    Douma S; Petidis K; Doumas M; Papaefthimiou P; Triantafyllou A; Kartali N; Papadopoulos N; Vogiatzis K; Zamboulis C
    Lancet; 2008 Jun; 371(9628):1921-6. PubMed ID: 18539224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.